JP2006520377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520377A5 JP2006520377A5 JP2006506335A JP2006506335A JP2006520377A5 JP 2006520377 A5 JP2006520377 A5 JP 2006520377A5 JP 2006506335 A JP2006506335 A JP 2006506335A JP 2006506335 A JP2006506335 A JP 2006506335A JP 2006520377 A5 JP2006520377 A5 JP 2006520377A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- testosterone
- esters
- undecanoate
- vol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 229960003604 testosterone Drugs 0.000 claims 7
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical group C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 6
- 239000003981 vehicle Substances 0.000 claims 6
- 239000004359 castor oil Substances 0.000 claims 5
- 235000019438 castor oil Nutrition 0.000 claims 5
- 239000006184 cosolvent Substances 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 5
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 4
- -1 testosterone ester Chemical class 0.000 claims 4
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims 4
- 229960000746 testosterone undecanoate Drugs 0.000 claims 4
- 150000003515 testosterones Chemical class 0.000 claims 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical class CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 4
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 4
- 229960002903 benzyl benzoate Drugs 0.000 claims 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 3
- 238000010255 intramuscular injection Methods 0.000 claims 3
- 239000007927 intramuscular injection Substances 0.000 claims 3
- SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 claims 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 206010052649 Primary hypogonadism Diseases 0.000 claims 2
- 206010059594 Secondary hypogonadism Diseases 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 2
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-M pentadecanoate Chemical compound CCCCCCCCCCCCCCC([O-])=O WQEPLUUGTLDZJY-UHFFFAOYSA-M 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 201000010789 Spermatic Cord Torsion Diseases 0.000 claims 1
- 206010043315 Testicular failure Diseases 0.000 claims 1
- 206010043356 Testicular torsion Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- DUGUIFNLXSKLLQ-UHFFFAOYSA-N [3-hydroxy-2,2-bis(hydroxymethyl)propyl] decanoate Chemical compound CCCCCCCCCC(=O)OCC(CO)(CO)CO DUGUIFNLXSKLLQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 125000005534 decanoate group Chemical class 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical class CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300399 | 2003-03-14 | ||
| PCT/IB2004/000716 WO2004080383A2 (en) | 2003-03-14 | 2004-03-15 | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520377A JP2006520377A (ja) | 2006-09-07 |
| JP2006520377A5 true JP2006520377A5 (https=) | 2007-04-05 |
| JP4680891B2 JP4680891B2 (ja) | 2011-05-11 |
Family
ID=32748728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506335A Expired - Lifetime JP4680891B2 (ja) | 2003-03-14 | 2004-03-15 | 許容可能な血清中テストステロン・レベルを信頼性高く達成するための方法及び医薬組成物 |
Country Status (39)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152858A1 (en) * | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| CA2604943C (en) * | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| EP2398461A1 (en) | 2009-02-18 | 2011-12-28 | Bayer Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| KR20150011346A (ko) * | 2012-04-06 | 2015-01-30 | 안타레스 팔마, 인코퍼레이티드 | 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법 |
| CN104780914B (zh) * | 2012-05-09 | 2018-02-09 | 健康科学西部大学 | 前体脂质体睾酮制剂 |
| WO2014093818A2 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| ES2969984T3 (es) | 2013-02-11 | 2024-05-23 | Antares Pharma Inc | Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida |
| TW201521731A (zh) * | 2013-03-15 | 2015-06-16 | 利波辛股份有限公司 | 用於口服之脂平衡的長鏈睪固酮酯 |
| CN105744983B (zh) * | 2013-08-12 | 2019-12-27 | 纳米医学系统公司 | 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法 |
| US9956164B2 (en) | 2014-04-16 | 2018-05-01 | Veyx-Pharma Gmbh | Veterinary pharmaceutical composition and use thereof |
| WO2016033549A2 (en) * | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| CN105056115A (zh) * | 2015-08-05 | 2015-11-18 | 成都市飞龙水处理技术研究所 | 一种治疗化脓性睾丸炎的内服药物及其制备方法 |
| US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| US11311554B2 (en) | 2018-04-04 | 2022-04-26 | Slayback Pharma Llc | Pharmaceutical compositions of testosterone |
| AU2019308326B2 (en) * | 2018-07-20 | 2025-07-31 | Lipocine Inc. | Liver disease |
| KR102051808B1 (ko) * | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
| KR20210131305A (ko) * | 2018-12-14 | 2021-11-02 | 아세러스 바이오파마 인크. | 테스토스테론의 활성 에스테르 유도체, 조성물 및 그의 용도 |
| US11564933B2 (en) | 2019-04-12 | 2023-01-31 | Tolmar, Inc. | Methods of treating testosterone deficiency |
| WO2021067600A1 (en) * | 2019-10-03 | 2021-04-08 | Caren Pharmaceuticals, Inc. | Combination hormone formulations and therapies |
| US20230227492A1 (en) * | 2020-06-11 | 2023-07-20 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
| US12257257B2 (en) * | 2023-07-27 | 2025-03-25 | Lipocine, Inc. | Testosterone dodecanoate compositions and methods |
| KR20250176964A (ko) * | 2024-06-13 | 2025-12-22 | 주식회사 종근당 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164520A (en) * | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
| US4181721A (en) * | 1975-10-27 | 1980-01-01 | Schering Aktiengesellschaft | Depot preparations in an oily, unsaturated solution for intramuscular injection |
| GB1567515A (en) | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| US4242863A (en) * | 1978-03-16 | 1981-01-06 | Caterpillar Tractor Co. | Dual phase fuel vaporizing combustor |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| CN1102095A (zh) | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) * | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| KR100499438B1 (ko) * | 1997-12-03 | 2005-07-07 | 머크 앤드 캄파니 인코포레이티드 | 수소화 피마자유를 함유하는 지속성 주사제 |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| NZ508299A (en) | 1998-06-19 | 2003-04-29 | Akzo Nobel Nv | Testosterone derivative |
| AU768537B2 (en) | 1999-04-01 | 2003-12-18 | Merck Sharp & Dohme B.V. | Formulation comprising testosteron undecanoate and castor oil |
| HUP0300128A3 (en) * | 2000-02-15 | 2004-03-29 | Schering Ag | Male contraceptive composition comprising norethisterone and its use |
| US20050101517A1 (en) | 2000-08-23 | 2005-05-12 | Henrick De Nijs | Novel testosterone ester formulation for human use |
-
2004
- 2004-03-11 JO JO200428A patent/JO2505B1/en active
- 2004-03-12 UY UY28231A patent/UY28231A1/es not_active Application Discontinuation
- 2004-03-12 MX MXPA04002395A patent/MXPA04002395A/es active IP Right Grant
- 2004-03-12 US US10/798,780 patent/US7718640B2/en active Active
- 2004-03-12 TW TW093106693A patent/TWI345976B/zh not_active IP Right Cessation
- 2004-03-15 RS YUP-2005/0702A patent/RS51537B/sr unknown
- 2004-03-15 AU AU2004218893A patent/AU2004218893B2/en not_active Expired
- 2004-03-15 EA EA200501819A patent/EA011568B1/ru unknown
- 2004-03-15 BR BRPI0400214A patent/BRPI0400214A8/pt not_active Application Discontinuation
- 2004-03-15 ES ES04075804T patent/ES2271772T3/es not_active Expired - Lifetime
- 2004-03-15 DK DK04075804T patent/DK1457208T3/da active
- 2004-03-15 AR ARP040100843A patent/AR043603A1/es not_active Application Discontinuation
- 2004-03-15 CN CN2010102249063A patent/CN101884639A/zh active Pending
- 2004-03-15 ME MEP-2008-145A patent/ME00149B/me unknown
- 2004-03-15 PE PE2004000272A patent/PE20041065A1/es active IP Right Grant
- 2004-03-15 SI SI200430105T patent/SI1457208T1/sl unknown
- 2004-03-15 CA CA002518910A patent/CA2518910C/en not_active Expired - Lifetime
- 2004-03-15 RU RU2005131724/15A patent/RU2354381C2/ru active
- 2004-03-15 PT PT04075804T patent/PT1457208E/pt unknown
- 2004-03-15 JP JP2006506335A patent/JP4680891B2/ja not_active Expired - Lifetime
- 2004-03-15 CN CN200480006912.4A patent/CN1761469B/zh not_active Expired - Lifetime
- 2004-03-15 PL PL04075804T patent/PL1457208T3/pl unknown
- 2004-03-15 ME MEP-145/08A patent/MEP14508A/xx unknown
- 2004-03-15 NZ NZ542321A patent/NZ542321A/en not_active IP Right Cessation
- 2004-03-15 DE DE602004001893T patent/DE602004001893T2/de not_active Expired - Lifetime
- 2004-03-15 HR HRP20050781AA patent/HRP20050781B1/hr not_active IP Right Cessation
- 2004-03-15 WO PCT/IB2004/000716 patent/WO2004080383A2/en not_active Ceased
- 2004-03-15 AT AT04075804T patent/ATE336251T1/de active
- 2004-03-15 EP EP04075804A patent/EP1457208B9/en not_active Expired - Lifetime
- 2004-03-15 EP EP06016949A patent/EP1743646A3/en not_active Withdrawn
- 2004-03-15 BR BR122017008910A patent/BR122017008910A8/pt not_active Application Discontinuation
- 2004-03-15 UA UAA200509571A patent/UA82510C2/uk unknown
- 2004-03-15 KR KR1020057017087A patent/KR100882378B1/ko not_active Expired - Lifetime
- 2004-03-15 KR KR1020087025443A patent/KR20080096717A/ko not_active Withdrawn
- 2004-03-15 CL CL200400527A patent/CL2004000527A1/es unknown
- 2004-03-21 SA SA04250040A patent/SA04250040B1/ar unknown
-
2005
- 2005-08-24 IL IL170473A patent/IL170473A/en active IP Right Grant
- 2005-09-20 CR CR7999A patent/CR7999A/es not_active Application Discontinuation
- 2005-10-07 CO CO05102559A patent/CO5700724A2/es not_active Application Discontinuation
- 2005-10-12 EC EC2005006095A patent/ECSP056095A/es unknown
- 2005-10-12 IS IS8069A patent/IS2565B/is unknown
- 2005-10-13 NO NO20054711A patent/NO335179B1/no unknown
- 2005-10-13 ZA ZA200508313A patent/ZA200508313B/en unknown
-
2006
- 2006-11-16 CY CY20061101678T patent/CY1105794T1/el unknown
-
2007
- 2007-01-02 ZA ZA200700046A patent/ZA200700046B/xx unknown
- 2007-05-16 RU RU2007118196/15A patent/RU2007118196A/ru not_active Application Discontinuation
-
2009
- 2009-02-24 US US12/391,655 patent/US8338395B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520377A5 (https=) | ||
| RU2007118196A (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
| KR101749514B1 (ko) | 비타민 ｄ 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물 | |
| CA2867419C (en) | Use of tetracycline compositions for wound treatment and skin restoration | |
| CN1248738C (zh) | 用于人的睾酮酯制剂 | |
| KR102297951B1 (ko) | 포스파티딜콜린을 포함하는 분무가능한 국소용 담체 및 조성물 | |
| CA2979051C (en) | Topical compositions comprising a corticosteroid | |
| Meriggiola et al. | Progestin-androgen combination regimens for male contraception | |
| WO2020089891A9 (en) | Topical minocycline foamable compositions | |
| EP2515866A2 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| RS52671B (sr) | Poboljšani gel testosterona i postupak korišćenja | |
| JP5369389B2 (ja) | 痔疾治療用組成物 | |
| CN107847435B (zh) | 用于治疗直肠的炎性变化的药物制剂 | |
| JP2538816B2 (ja) | 動物用ビタミンａ製剤 | |
| AU2005201035B2 (en) | Treatment of inflammatory conditions of the intestine | |
| JP5815900B2 (ja) | 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法 | |
| CA2496637C (en) | Treatment of inflammatory conditions of the intestine using high density lipoprotein | |
| Felden et al. | Comparative Clinical Effects of Hydromorphone and Morphine: A Meta-Analysis | |
| RU2642244C2 (ru) | Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием |